However, recent MRD studies conducted using RT-qPCR made very clear that even in CBF/NPM1 positive AML the persistence of MRD at any time point during therapy significantly reduce the duration of response and survival [29,30]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.